clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-290Research ArticleФАРМАКОЭКОНОМИКАPHARMACOECONOMICSКлинико-экономические аспекты лечения артериальной гипертонии: по данным исследования ALLHATГороховаС. Г.clinvest@mail.ru200326062008026570Copyright © Горохова С.Г., 20182018Горохова С.Г.Горохова С.Г.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/290фармакоэкономикаартериальная гипертонияисследование ALLHATанализ минимизации затратReferencesThe ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA 2002; 288: 2981-2997.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA 2002; 288: 2981-2997.Appel L.G. The Verdict from ALLHAT – thiazide diuretics are the preferred initial therapy for hypertension // JAMA 2002; 288: 339-342.Appel L.G. The Verdict from ALLHAT – thiazide diuretics are the preferred initial therapy for hypertension // JAMA 2002; 288: 339-342.Ambrosioni E. Pharmacoeconomics of hypertension management. The place of combination therapy // Pharmacoeconomics 2001; 19 (4): 337-347.Ambrosioni E. Pharmacoeconomics of hypertension management. The place of combination therapy // Pharmacoeconomics 2001; 19 (4): 337-347.Weber M.A. // J Clin Hypertens 2003; 5: 9-13.Weber M.A. // J Clin Hypertens 2003; 5: 9-13.Авксентьева М.В., Воробьев П.А., Герасимов В.Б., Горохова С.Г., Кобина С.А. Экономическая оценка эффективности лекарственной терапии (фармакоэкономический анализ). М.: Ньюдиамед, 2000. – 80 с.Авксентьева М.В., Воробьев П.А., Герасимов В.Б., Горохова С.Г., Кобина С.А. Экономическая оценка эффективности лекарственной терапии (фармакоэкономический анализ). М.: Ньюдиамед, 2000. – 80 с.Международные рекомендации Всемирной организации здравоохранения, Международного общества по артериальной гипертонии (ВОЗ, МОАГ). М., 1999.Международные рекомендации Всемирной организации здравоохранения, Международного общества по артериальной гипертонии (ВОЗ, МОАГ). М., 1999.Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации (ДАГ-1) // Русский мед. журнал 2000;9: 91-8.Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации (ДАГ-1) // Русский мед. журнал 2000;9: 91-8.Преображенский Д.В., Сидоренко Б.А., Ботыралиев Т.А. Ингибиторы АПФ и АТ1-блокаторы в клинической практике. М., 2002.Преображенский Д.В., Сидоренко Б.А., Ботыралиев Т.А. Ингибиторы АПФ и АТ1-блокаторы в клинической практике. М., 2002.Dahlof B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., Wester P. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) // Lancet 1991;338: 1281-5.Dahlof B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., Wester P. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) // Lancet 1991;338: 1281-5.Packer M., Pool-Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitors, lisinopril, on morbidity and mortality in chronic heart failure // Circulation, 1999; 100: 2312-2318.Packer M., Pool-Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitors, lisinopril, on morbidity and mortality in chronic heart failure // Circulation, 1999; 100: 2312-2318.Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction // Lancet. 1994; 343: 1115-1122.Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction // Lancet. 1994; 343: 1115-1122.The EUCLID study group. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria // Lancet 1997;349: 1787-92.The EUCLID study group. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria // Lancet 1997;349: 1787-92.Преображенский Д.В., Сидоренко Б.А., Шабаева Е.Н. Амлодипин - антагонист кальция третьего поколения // Кардиология, 1998; 2: 66-73.Преображенский Д.В., Сидоренко Б.А., Шабаева Е.Н. Амлодипин - антагонист кальция третьего поколения // Кардиология, 1998; 2: 66-73.Abernethy D.R. The pharmacokinetic profile of amlodipine // Am Heart J 1989; 189: 1100-1103.Abernethy D.R. The pharmacokinetic profile of amlodipine // Am Heart J 1989; 189: 1100-1103.Liebson P.R., Grandits G.A., Dianzumba S. et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS) // Circulation 1995; 91: 698-706.Liebson P.R., Grandits G.A., Dianzumba S. et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS) // Circulation 1995; 91: 698-706.Byington R.P., Miller M.E., Herrington D., Riley W., Pitt B., Furberg C.D., Hunninghake D.B., Mancini G.B.J. Rationale, design and baseline characteristics of the prospective randomized evaluation of the vascular effects of Norvasc trial (PREVENT) // Am J Cardiol 1997; 80: 1087-90.Byington R.P., Miller M.E., Herrington D., Riley W., Pitt B., Furberg C.D., Hunninghake D.B., Mancini G.B.J. Rationale, design and baseline characteristics of the prospective randomized evaluation of the vascular effects of Norvasc trial (PREVENT) // Am J Cardiol 1997; 80: 1087-90.Packer M., O’Connor M., Ghali J.K., Pressler M.L. Effect of amlodipine on morbidity and mortality in severe chronic heart failure // N Engl J Med 1996;335:1107-14.Packer M., O’Connor M., Ghali J.K., Pressler M.L. Effect of amlodipine on morbidity and mortality in severe chronic heart failure // N Engl J Med 1996;335:1107-14.Jorgensen B., Simonsen S., Forfang K. Amlodipine in post-angioplasty ischaemia: results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) // Eur Heart J 1999; 20 Suppl: 285.Jorgensen B., Simonsen S., Forfang K. Amlodipine in post-angioplasty ischaemia: results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) // Eur Heart J 1999; 20 Suppl: 285.Wassertheil-Smoller S., Blaufox M.D., Oberman A.S., Langford H.G., Davis B.R., Wylie-Rosett J. The trial of antihypertensive interventions and management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension // Arch Intern Med 1992; 152: 131-6.Wassertheil-Smoller S., Blaufox M.D., Oberman A.S., Langford H.G., Davis B.R., Wylie-Rosett J. The trial of antihypertensive interventions and management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension // Arch Intern Med 1992; 152: 131-6.SHEP Cooperative Research GroupPrevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) // JAMA 1991; 265: 3255-64.SHEP Cooperative Research GroupPrevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) // JAMA 1991; 265: 3255-64.Casiglia E., Spolaore P., Mazza A., Ginocchio G., Colangeli G., Onesto C., Di Menza G., Pegoraro L., Ambrosio G.B. Effect of 2 different approaches on total and cardiovascular mortality in a cardiovascular study in the elderly (CASTEL) // Jpn Heart J 1994; 35: 589-600.Casiglia E., Spolaore P., Mazza A., Ginocchio G., Colangeli G., Onesto C., Di Menza G., Pegoraro L., Ambrosio G.B. Effect of 2 different approaches on total and cardiovascular mortality in a cardiovascular study in the elderly (CASTEL) // Jpn Heart J 1994; 35: 589-600.
The authors declare that there are no conflicts of interest present.